Ironwood Lifts 2026 Outlook on Robust Q2 LINZESS Sales and Pipeline Progress with Apraglutide

summarizeSummary

Ironwood raised full-year 2026 guidance after Q2 LINZESS sales grew 14% to $282 million, repaid $200 million in convertible notes, and started a pivotal Phase 3 trial for apraglutide.

check_boxKey Events · Earnings and Guidance · IRWD

• Raised Full-Year 2026 Guidance

  LINZESS U.S. net sales guidance raised to $1.15–$1.20 billion (>30% YoY growth); total revenue guidance raised to $460–$485 million; adjusted EBITDA guidance raised to >$310 million.

• Strong Q2 LINZESS Performance

  Q2 LINZESS U.S. net sales of $282 million, up 14% YoY, driven by 4% demand growth and improved net price. Commercial margin expanded to 78% from 69%.

• Q2 Financial Results

  Total revenue of $113 million, GAAP net income of $51 million ($0.31 per share), and adjusted EBITDA of $83 million. Cash from operations was $58.3 million.

• Debt Reduction

  Repaid $200 million convertible senior notes at maturity using cash on hand, reducing leverage. Revolving credit facility balance remains $385 million.

auto_awesomeAnalysis · IRWD · Life Sciences

A beat-and-raise quarter underscores Ironwood's momentum: Q2 LINZESS U.S. net sales climbed 14% to $282 million, propelling total revenue to $113 million and GAAP net income to $51 million. Reflecting improved net price and mid-single-digit demand growth, management raised full-year LINZESS sales guidance to $1.15–$1.20 billion (up from $1.125–$1.175 billion) and total revenue to $460–$485 million. The balance sheet strengthened further as the company repaid its $200 million convertible notes with cash on hand. Meanwhile, the initiation of the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel syndrome marks a key pipeline catalyst. Together, the upwardly revised financials, debt reduction, and pipeline advancement materially enhance the investment thesis.